Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

Rhea-AI Summary

Coherus Oncology (Nasdaq: CHRS) will release its full year and fourth quarter 2025 financial results after market close on Monday, March 9, 2026. A management conference call and webcast will begin at 4:30 p.m. ET the same day, with a replay posted on the company investor website.

Investors can pre-register for dial-in details and PIN, and the press release and related materials will be available on the Coherus investor site before the call.

Key Figures

Shares in Feb 2026 offering: 28,600,000 shares Offering price: $1.75 per share Gross proceeds: $50.1 million +5 more

8 metrics

Shares in Feb 2026 offering 28,600,000 shares Underwritten public offering of common stock

Offering price $1.75 per share Pricing of Feb 2026 public offering

Gross proceeds $50.1 million Feb 2026 underwritten public offering

2025 net revenue $42.2M vs $26.4M Preliminary full-year 2025 vs 2024 revenue

Q4 2025 revenue $12.7M vs $7.7M Preliminary Q4 2025 vs Q4 2024 revenue

LOQTORZI revenue 2025 $40.8 million Preliminary 2025 LOQTORZI sales contribution

Cash & securities $172.1 million Estimated as of December 31, 2025

ATM program size $64,880,054 At-the-market offering capacity under Sales Agreement

Market Reality Check

Price: $1.67 Vol: Volume 1,035,490 is at 0....

low vol

$1.67 Last Close

Volume Volume 1,035,490 is at 0.52x the 20-day average of 1,983,257 shares. low

Technical Shares at $1.67, trading above the 200-day MA of $1.31 while 36.16% below the 52-week high.

Peers on Argus

CHRS was down 1.18% with mixed peer moves: AGEN +1.99%, GLSI +1.43%, THTX +0.89%...

CHRS was down 1.18% with mixed peer moves: AGEN +1.99%, GLSI +1.43%, THTX +0.89%, TIL -1.11%, MCRB -1.91%, pointing to stock-specific trading rather than a sector-wide move.

Historical Context

5 past events · Latest: Feb 23 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 23	Investor conferences	Neutral	-0.6%	Announcement of March 2026 investor conference presentations and webcasts.
Feb 17	Equity offering close	Negative	+1.2%	Closing of 28.6M-share underwritten public offering of common stock.
Feb 12	Offering priced	Negative	-19.9%	Pricing of 28.6M-share public stock offering at $1.75 per share.
Feb 12	Offering proposed	Negative	-19.9%	Proposed underwritten equity offering from effective Form S-3 shelf.
Jan 06	JPM conference	Neutral	-5.6%	Planned presentation at J.P. Morgan Healthcare Conference with webcast replay.

Pattern Detected

Recent financings drew sharp negative reactions, while conference-related news has seen modest or mixed price responses.

Recent Company History

Over the last few months, CHRS has focused on financing and investor outreach. Multiple February 2026 equity offerings from its shelf registration coincided with steep one-day declines of about -19.9%, while the closing of the deal saw a small gain. Conference participation in January and February produced mild to moderate declines, suggesting investors have reacted more strongly to dilution events than to corporate visibility updates.

Regulatory & Risk Context

Active S-3 Shelf · $150.0 million

Shelf Active

Active S-3 Shelf Registration 2025-11-13

$150.0 million registered capacity

The company has an effective Form S-3 shelf filed on November 13, 2025, allowing it to offer up to $150.0 million in various securities via prospectus supplements, as evidenced by multiple recent 424B5 takedowns.

Market Pulse Summary

This announcement schedules Coherus’ full-year and Q4 2025 results for March 9, 2026, following rece...

Analysis

This announcement schedules Coherus’ full-year and Q4 2025 results for March 9, 2026, following recent financings and preliminary updates that showed revenue of $42.2M and cash of $172.1M. Investors may compare the final numbers to these earlier figures and assess how recent equity offerings and ATM capacity are being used. Key items to watch include LOQTORZI performance, operating losses, and any updated funding or development plans.

Key Terms

regulation fd, at-the-market offering, shelf registration, form s-3, +4 more

8 terms

regulation fd regulatory

"for complying with its disclosure obligations under Regulation FD."

Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.

at-the-market offering financial

"in an at-the-market offering program. The company may offer and sell"

An at-the-market offering is a method companies use to sell new shares of stock directly into the open market over time, rather than all at once. This allows them to raise money gradually, similar to selling small pieces of a product instead of a large batch. For investors, it means the company can access funding more flexibly, but it may also increase the supply of shares and influence the stock’s price.

shelf registration regulatory

"is launching a public offering of common stock from its existing shelf registration."

Shelf registration is when a company gets permission ahead of time to sell new stocks or bonds over a period of time instead of all at once. It matters to investors because it lets a company raise money quickly when needed, but it can also change the value of existing shares if many new ones are sold.

form s-3 regulatory

"filed a shelf registration statement on Form S-3 to offer and sell up to"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

schedule 13g regulatory

"received a Schedule 13G reporting that the Timothy G. Youngquist"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

restricted stock units financial

"he received 375,000 restricted stock units of Coherus Oncology common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

stock option financial

"He was also granted a stock option for 750,000 shares of common stock"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

phase 1b medical

"to support a Phase 1b study in metastatic castration-resistant prostate cancer."

"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.

AI-generated analysis. Not financial advice.

REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after market close on Monday, March 9, 2026. Starting at 4:30 p.m. Eastern Time on March 9, 2026, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.

A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call.

Conference Call Information

When: Monday, March 9, 2026, starting at 4:30 p.m. Eastern Standard Time

To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register-conf.media-server.com/register/BI343f960d41224739b123cc4c86fdce7a

Webcast: https://edge.media-server.com/mmc/p/2otjwz7w

The press release with the full year and fourth quarter 2025 financial results and related materials will be available at https://investors.coherus.com before the start of the conference call.

A live and archived webcast will be available on the “Investors” section of the Coherus website at https://investors.coherus.com/events-presentations.

Please dial in 15 minutes early to ensure a timely connection to the call.

Disclosure Information

Coherus uses the https://investors.coherus.com website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. 

About Coherus Oncology

Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI^® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, prostate, head & neck, colorectal and other cancers. The Company’s strategy is to grow sales of LOQTORZI in R/M Nasopharyngeal Carcinoma and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as through its partners, driving sales multiples and synergies from proprietary combinations.

Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors, including head and neck squamous cell carcinoma, colorectal cancer, gastric cancer, and esophageal cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma.

LOQTORZI^® is a registered trademark of Coherus Oncology, Inc.
©2026 Coherus Oncology, Inc. All rights reserved.

Coherus Oncology Contact Information:

For Investors:

Carrie Graham
Vice President, Investor Relations & Advocacy
IR@coherus.com

FAQ

When will Coherus Oncology (CHRS) release full year and Q4 2025 results?

Coherus will release full year and Q4 2025 results after market close on March 9, 2026. According to Coherus, the company will publish the press release and related materials on its investor website before the conference call begins at 4:30 p.m. ET.

How can investors join the Coherus Oncology (CHRS) March 9, 2026 earnings call?

Investors can join by pre-registering to receive dial-in details and a personal PIN before the call. According to Coherus, pre-registration is required to obtain dial-in information and the PIN to access the live conference call.

What time and webcast link will Coherus Oncology (CHRS) use for the March 9, 2026 call?

The live call starts at 4:30 p.m. Eastern Time on March 9, 2026 and will be webcast live. According to Coherus, the webcast will be available at the company investor site and via the provided media-server webcast link.

Will a replay of the Coherus Oncology (CHRS) March 9, 2026 webcast be available?

Yes, a replay of the webcast will be posted after the live call on the company investor site. According to Coherus, the live and archived webcast will be available in the Investors section following the conclusion of the call.